CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone

American Journal of Pathology

Volumn 178, Issue 5, 2011, Pages 2377-2388

  Ouellet, Véronique ^a,b   Tiedemann, Kerstin ^b   Mourskaia, Anna ^a,b   Fong, Jenna E ^b   Tran Thanh, Danh ^c   Amir, Eitan ^d   Clemons, Mark ^e   Perbal, Bernard ^f   Komarova, Svetlana V ^b   Siegel, Peter M ^a,b,g  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e OTTAWA REGIONAL CANCER CENTRE   (Canada)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g L ORÉAL RECHERCHE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEPHROBLASTOMA OVEREXPRESSED PROTEIN; NUCLEAR FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT PROTEIN; TUMOR MARKER;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE METASTASIS; BREAST; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOCYTE MACROPHAGE PRECURSOR CELL; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL CULTURE; TUMOR XENOGRAFT;

EID: 79959244877     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.01.033     Document Type: Article

References (68)

1. Coleman RE: Skeletal complications of malignancy. Cancer 1997, 80:1588-1594
2. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer 2006, 106:1624-1633
3. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593
4. Costa L, Major PP: Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009, 6:163-174
5. Neville-Webbe HL, Coleman RE: Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 2010, 46:1211-1222
6. Rose AA, Siegel PM: Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 2010, 6:55-74
7. Brigstock DR, Goldschmeding R, Katsube KI, Lam SC, Lau LF, Lyons K, Naus C, Perbal B, Riser B, Takigawa M, Yeger H: Proposal for a unified CCN nomenclature. Mol Pathol 2003, 56:127-128
8. Perbal B: CCN proteins: multifunctional signalling regulators. Lancet 2004, 363:62-64
9. Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem MF, Finley GG, Quirke P, Goddard AD, Hillan KJ, Gurney AL, Botstein D, Levine AJ: WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 1998, 95:14717-14722
10. Brigstock DR: The CCN family: a new stimulus package. J Endocrinol 2003, 178:169-175
11. Leask A, Abraham DJ: All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006, 119: 4803-4810
12. Zuo GW, Kohls CD, He BC, Chen L, Zhang W, Shi Q, Zhang BQ, Kang Q, Luo J, Luo X, Wagner ER, Kim SH, Restegar F, Haydon RC, Deng ZL, Luu HH, He TC, Luo Q: The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis. Histol Histopathol 2010, 25:795-806
13. Fu CT, Bechberger JF, Ozog MA, Perbal B, Naus CC: CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J Biol Chem 2004, 279: 36943-36950
14. Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I, Elder DE, Perbal B, Herlyn M: Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 2008, 27:2552-2560
15. Gupta N, Wang H, McLeod TL, Naus CC, Kyurkchiev S, Advani S, Yu J, Perbal B, Weichselbaum RR: Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV). Mol Pathol 2001, 54:293-299
16. Vallacchi V, Daniotti M, Ratti F, Di Stasi D, Deho P, De Filippo A, Tragni G, Balsari A, Carbone A, Rivoltini L, Parmiani G, Lazar N, Perbal B, Rodolfo M: CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res 2008, 68:715-723
17. Benini S, Perbal B, Zambelli D, Colombo MP, Manara MC, Serra M, Parenza M, Martinez V, Picci P, Scotlandi K: In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 2005, 24:4349-4361
18. Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi S, Serra M, Astolfi A, Bertoni F, Alami J, Yeger H, Picci P, Scotlandi K: The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol 2002, 160:849-859
19. Perbal B, Lazar N, Zambelli D, Lopez-Guerrero JA, Llombart-Bosch A, Scotlandi K, Picci P: Prognostic relevance of CCN3 in Ewing sarcoma. Hum Pathol 2009, 40:1479-1486
20. Maillard M, Cadot B, Ball RY, Sethia K, Edwards DR, Perbal B, Tatoud R: Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol 2001, 54:275-280
21. Perbal B, Zuntini M, Zambelli D, Serra M, Sciandra M, Cantiani L, Lucarelli E, Picci P, Scotlandi K: Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res 2008, 14:701-709
22. Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM: Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 2007, 5:1001-1014
23. Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM: Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 2010, 16:2147-2156
24. Chevalier G, Yeger H, Martinerie C, Laurent M, Alami J, Schofield PN, Perbal B: novH: differential expression in developing kidney and Wilm's tumors. Am J Pathol 1998, 152:1563-1575
25. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45
26. Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM: Signaling through ShcA is required for transforming growth factor β- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol Cell Biol 2008, 28:3162-3176
27. Pasmant E, Ortonne N, Rittie L, Laurendeau I, Levy P, Lazar V, Parfait B, Leroy K, Dessen P, Valeyrie-Allanore L, Perbal B, Wolkenstein P, Vidaud M, Vidaud D, Bieche I: Differential expression of CCN1/CYR61. CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis, J Neuropathol Exp Neurol 2010, 69:60-69
28. Perbal B, Martinerie C, Sainson R, Werner M, He B, Roizman B: The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell-adhesion signaling. Proc Natl Acad Sci U S A 1999, 96:869-874
29. Armstrong S, Pereverzev A, Dixon SJ, Sims SM: Activation of P2X7 receptors causes isoform-specific translocation of protein kinase C in osteoclasts. J Cell Sci 2009, 122:136-44
30. 2+/protein kinase C and transforming growth factor-β/ MAPK signaling pathways. J Biol Chem 2009, 284:33662-33670
31. 2+ accelerates nuclear translocation of nuclear factor κB in osteoclasts. J Biol Chem 2003, 278: 8286-8293
32. Guo Y, Tiedemann K, Khalil JA, Russo C, Siegel PM, Komarova SV: Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. Bone 2008, 43:386-393
33. Sin WC, Tse M, Planque N, Perbal B, Lampe PD, Naus CC: Matricellular protein CCN3 (NOV) regulates actin cytoskeleton reorganization. J Biol Chem 2009, 284:29935-29944
34. Aslakson CJ, Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992, 52:1399-1405
35. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL: Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 2005, 3:1-13
36. Casimiro S, Guise TA, Chirgwin J: The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009, 310:71-81
37. Heath E, Tahri D, Andermarcher E, Schofield P, Fleming S, Boulter CA: Abnormal skeletal and cardiac development, cardiomyopathy, muscle atrophy and cataracts in mice with a targeted disruption of the Nov (Ccn3) gene. BMC Dev Biol 2008, 8:18
38. Katsuki Y, Sakamoto K, Minamizato T, Makino H, Umezawa A, Ikeda MA, Perbal B, Amagasa T, Yamaguchi A, Katsube K: Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1. Biochem Biophys Res Commun 2008, 368:808-814
39. Minamizato T, Sakamoto K, Liu T, Kokubo H, Katsube K, Perbal B, Nakamura S, Yamaguchi A: CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways. Biochem Biophys Res Commun 2007, 354:567-573
40. Rydziel S, Stadmeyer L, Zanotti S, Durant D, Smerdel-Ramoya A, Canalis E: Nephroblastoma overexpressed (Nov) inhibits osteoblastogenesis and causes osteopenia. J Biol Chem 2007, 282:19762-19772
41. Dougall WC, Chaisson M: The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006, 25:541-549
42. Khosla S: Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055
43. Ooi LL, Zheng Y, Stalgis-Bilinski K, Dunstan CR: The bone remodeling environment is a factor in breast cancer bone metastasis. Bone 201148:66-70
44. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL: The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000, 141:4768-4776
45. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999, 96:3540-3545
46. Islam S, Hassan F, Tumurkhuu G, Dagvadorj J, Koide N, Naiki Y, Yoshida T, Yokochi T: Receptor activator of nuclear factor-κB ligand induces osteoclast formation in RAW 264.7 macrophage cells via augmented production of macrophage-colony-stimulating factor. Microbiol Immunol 2008, 52:585-590
47. Li CL, Martinez V, He B, Lombet A, Perbal B: A role for CCN3 (NOV) in calcium signalling. Mol Pathol 2002, 55:250-261
48. Lombet A, Planque N, Bleau AM, Li CL, Perbal B: CCN3 and calcium signaling. Cell Commun Signal 2003, 1:1
49. 2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev 2009, 231:241-256
50. Dhar A, Ray A: The CCN family proteins in carcinogenesis. Exp Oncol 2010, 32:2-9
51. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE: Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 2004, 11:781-791
52. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, Said JW, Gornbein J, Koeffler HP: Breast cancer: Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 2001, 276:14187-14194
53. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549
54. Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, Eguchi T, Sasaki A, Takigawa M: Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 2006, 21:1045-1059
55. Ghayad SE, Vendrell JA, Bieche I, Spyratos F, Dumontet C, Treilleux I, Lidereau R, Cohen PA: Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol 2009, 42:87-103
56. Vendrell JA, Magnino F, Danis E, Duchesne MJ, Pinloche S, Pons M, Birnbaum D, Nguyen C, Theillet C, Cohen PA: Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol 2004, 32:397-414
57. Joliot V, Martinerie C, Dambrine G, Plassiart G, Brisac M, Crochet J, Perbal B: Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1-induced nephroblastomas. Mol Cell Biol 1992, 12:10-21
58. Planque N, Perbal B: A structural approach to the role of CCN (CYR61/ CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 2003, 3:15
59. Glukhova L, Angevin E, Lavialle C, Cadot B, Terrier-Lacombe MJ, Perbal B, Bernheim A, Goguel AF: Patterns of specific genomic alterations associated with poor prognosis in high-grade renal cell carcinomas. Cancer Genet Cytogenet 2001, 130:105-110
60. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massague J: Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78
61. Katsube K, Ichikawa S, Katsuki Y, Kihara T, Terai M, Lau LF, Tamamura Y, Takeda S, Umezawa A, Sakamoto K, Yamaguchi A: CCN3 and bone marrow cells. J Cell Commun Signal 2009, 3:135-145
62. Canalis E: Nephroblastoma overexpressed (Nov) is a novel bone morphogenetic protein antagonist. Ann N Y Acad Sci 2007, 1116:50-58
63. Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA: The calcineurin/ nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 2004, 279: 13984-13992
64. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, Kumegawa M, Kimura T, Takeya T: Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 2002, 277:41147-41156
65. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901
66. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E, Takayanagi H: Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005, 202:1261-1269
67. McCallum L, Lu W, Price S, Lazar N, Perbal B, Irvine AE: CCN3: a key growth regulator in Chronic Myeloid Leukaemia. J Cell Commun Signal 2009, 3:115-124
68. Le Dreau G, Kular L, Nicot AB, Calmel C, Melik-Parsadaniantz S, Kitabgi P, Laurent M, Martinerie C: NOV/CCN3 upregulates CCL2 and CXCL1 expression in astrocytes through β1 and β5 integrins. Glia 2010, 58:1510-1521